No matching results for ''
Tip: Try a valid symbol or a specific company name for relevant results
Canada markets closed
Cipher Pharmaceuticals Inc. (CPH.TO)
Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
At close: 03:57PM EDT
155 reactions on $CPH.TO conversation
Sign in to post a message.
I just bought few shares today. It’s looking good numbers.
Good Q1 2022 results just released. EPS of $0.08 was better than I expected! Absorica declined but Epuris revenue picked up the slack.
An interesting tidbit of information regarding MOB-015 potential:
"In Canada, according to IQVIA, the total prescription market for Onychomycosis was greater than $75 million CDN at December 31, 2021, with a single product having over 90% market share."
Moberg estimates the annual global sales potential for MOB-015 to be USD$250-500M.
Below are estimates for the market size in each region (some estimates are from as late as 2017 and have grown significantly since then):
Region (Company) $marketUSD
Canada (Cipher) $57M
Korea (DongKoo) $40M
Japan (Taisho) $290M
Europe (Bayer) $207M
Scandinavia (Allderma) $10M
USA (Moberg) $150M-300M
I remain optimistic that Cipher has its best days ahead. Decent earnings and potential revenue generators in the pipeline result in my maintaining a position. Like most stocks there is always a speculative component but a stock with good cash reserves, real earnings and potential additional revenue generators with a low PE leads me to believe that our next bit of good news will result in more folks recognizing this stock.
-Favorable phase 3 study topline results for CF-101 (for plaque psoriasis)
-Positive update on the second phase 3 study for MOB-015 (for nail fungus)
-A product acquisition using some of the $20.5M cash
-More aggressive monthly share buybacks via the NCIB
-CF-101 results show inferiority to Otezla®
-MOB-015 results show visible nail whitening (again)
-Licensing revenue from Absorica continues to decline
-The cash stockpile is used in an imprudent manner
Maybe they should look at a dividend
A buyback of 137,400 shares was released on SEDI yesterday May 10, 2022. This brings the total number of shares bought back under the current NCIB to 1,167,000 (or 75% of the total allowed).
CF101 Phase 3 study topline results were expected in Q1 2022 according to Cipher's most recent MD&A and Can-Fite BioPharma's own website. We should be seeing this news any day now. Over one million Canadians suffer from psoriasis. Strong study results should serve as a catalyst since Cipher holds the Canadian distribution rights for CF101.
A massive buyback of 196,300 shares was just released on SEDI this evening April 11, 2022. This is Cipher's biggest share buyback yet on this latest NCIB which runs from Sept 10, 2021 to Sept 9, 2022 and allows them to buyback & cancel up to 1,541,445 shares (or 10%) of the public float. This brings the total number of shares bought back under the current NCIB to 1,029,600 (or 67% of the total allowed).
In my opinion, this is the optimum use of the $20.5M cash on the balance sheet while we await results of the second Phase 3 study for MOB-015. Share buybacks are superior to special dividends or a risky product acquisition. I know management is keeping their eyes open for a potential legacy product to buy in an effort to bolster revenue as Absorica declines, but I hope they err on the side of prudence. After all, the first Phase 3 study for MOB-015 already showed safety and efficacy - it just needed reformulation to prevent nail discoloration. The total Rx market for Onychomycosis in Canada is USD $60+ million, and hopefully MOB-015 will be able to take a big chunk of that.
Marekt Cap $35 M / Cash $10 Million/ Shares Out 26 M/ Undiscovered and Profitable Biotech with significant upside potential ..Many new attractive Product launches and approvals expected within this year . I think this one is the hottest pick in the canadian healthcare sector my tgt is $10 for next 1-2 years .GL
( plecanatide) for the treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation which acquired from Synergy Pharma and MOB-015 for the treatment of Onychomycosis have the biggest potential and both awaiting approval expected in 2H 2019 .
Cipher Pharma (CPH.TO)
Market Cap: $35 Million
Cash: $10 Million
Shares Out: 26 Million
Cipher anticipates several key milestones in 2019 that will continue the growth of its Canadian commercial platform, including:
*Regulatory approval for plecanatide from Health Canada in Q4 2019
*Regulatory approval for A-101 from Health Canada in Q4 2019
*Commercial launch of XYDALBA (dalbavancin)
*North American top line results for MOB-015 in Q4 2019
Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide)..Oct. 18, 2019
It is estimated that one in four Canadians has symptoms of constipation and an estimated 38% of Canadians report constipation within the previous 12 months.[B]According to IQVIA the total Canadian laxative and antispasmodic market (prescription and OTC) was valued at over CDN $200 million for the 12 months ending December 2018[/B] .
Cipher acquired the Canadian rights to develop, market, distribute and sell TRULANCE® from Bausch Health Companies Inc.
It was just announced yesterday they will potentially be buying back 10% of their public float via another normal course issuer bid. They already have 41% of shares held by insiders. Their last quarter was a blowout. Surprisingly strong revenue numbers from Epuris and Absorica. I think it's safe to say management has turned Cipher around and the trajectory will continue upwards from here. And with a PE of around 9 it continues to be a value entry point.
The Cipher / Sun Pharma distribution agreement in the United States has been extended through 2026 for the Absorica isotretinoin product.
Very impressive FY2021 results just released!
EPS surged 81% to $0.29 in 2021 (vs $0.16 in 2020)
Revenue remained steady at $21.9 million (vs $21.6 million)
Cash stockpile grew to $20.5 million (vs $9.1 million)
1.2 million shares repurchased and canceled
Operating expenses continued to decline
$0 debt on the balance sheet
I read this today on Moberg Pharma's website (Moberg is the same company that makes the popular Kerasal Nail® brand product):
"the potential revenue for MOB-015 ... is USD 50–100 million each in Japan/Canada"
Director just loaded up on shares. 13,000
This stock is very underpriced guys! Look at the milestones.. I bought today my last position before it climp at new highs ;)
Many Insider buying goes on!!
the kind of stock you buy now and sell too early at 3$ cause it races up to 5$. I had this stock back when it was 5$ and did well with it, it came back under my radar.
The nail fungus phase 3 looks interesting from a potential addition to the pipeline perspective.
The arbitration award holds that Cipher was in breach of contract and will be required to turn over the Canadian Drug Identification Number ("DIN") for Trulance to Bausch Health effective immediately. In addition, Cipher has been ordered to pay approximately $240,000 related to unpaid invoices associated with work which was previously completed by Bausch Health. The issue of whether Bausch Health is entitled to any additional amounts under the Agreement is deferred to a subsequent phase of the arbitration. As a result, the Company will impair approximately $5,400,000 USD in intangible assets related to upfront and milestone payments paid.
RBC sees ‘the strongest fundamental oil market set up in decades, maybe ever’
Yahoo Finance Canada
An Uber driver says she ditched her Toyota for a Tesla because her Camry cost $600 a week to fuel compared with $450 for leasing and charging a Model 3
Couche-Tard CEO: Soaring inflation sees fewer fill-ups, more sales of cheap beer & smokes
Yahoo Finance Canada
© 2022 Yahoo. All rights reserved.
About Our Ads